These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions. Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032 [TBL] [Abstract][Full Text] [Related]
26. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Takashita E; Ichikawa M; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Sugawara H; Sato A; Akimoto M; Mitamura K; Abe T; Yamazaki M; Watanabe S; Hasegawa H; Odagiri T Emerg Infect Dis; 2019 Nov; 25(11):2108-2111. PubMed ID: 31436527 [TBL] [Abstract][Full Text] [Related]
27. Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods. Patel MC; Mishin VP; De La Cruz JA; Chesnokov A; Nguyen HT; Wilson MM; Barnes J; Kondor RJG; Wentworth DE; Gubareva LV Antiviral Res; 2020 Oct; 182():104906. PubMed ID: 32798601 [TBL] [Abstract][Full Text] [Related]
28. Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil. Ince WL; Smith FB; O'Rear JJ; Thomson M J Infect Dis; 2020 Aug; 222(6):957-961. PubMed ID: 32253432 [TBL] [Abstract][Full Text] [Related]
29. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. Ikematsu H; Hayden FG; Kawaguchi K; Kinoshita M; de Jong MD; Lee N; Takashima S; Noshi T; Tsuchiya K; Uehara T N Engl J Med; 2020 Jul; 383(4):309-320. PubMed ID: 32640124 [TBL] [Abstract][Full Text] [Related]
30. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020. Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289 [TBL] [Abstract][Full Text] [Related]
31. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season. Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230 [TBL] [Abstract][Full Text] [Related]
32. Genomic Analysis of Influenza A and B Viruses Carrying Baloxavir Resistance-Associated Substitutions Serially Passaged in Human Epithelial Cells. Hickerson BT; Huang BK; Petrovskaya SN; Ilyushina NA Viruses; 2023 Dec; 15(12):. PubMed ID: 38140689 [TBL] [Abstract][Full Text] [Related]
33. Modeling mitigation of influenza epidemics by baloxavir. Du Z; Nugent C; Galvani AP; Krug RM; Meyers LA Nat Commun; 2020 Jun; 11(1):2750. PubMed ID: 32487990 [TBL] [Abstract][Full Text] [Related]
34. Polymerase Acidic Subunit I38T Mutant Influenza A(H3N2) Virus Isolated from a Pediatric Patient without Prior Baloxavir Marboxil Treatment in Mie Prefecture (November 2018). Yano T; Ochiai H; Akachi S; Matsumura Y Jpn J Infect Dis; 2020 Sep; 73(5):383-385. PubMed ID: 32475868 [No Abstract] [Full Text] [Related]
35. A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions. Koszalka P; Farrukee R; Mifsud E; Vijaykrishna D; Hurt AC Influenza Other Respir Viruses; 2020 Jul; 14(4):460-464. PubMed ID: 32045100 [TBL] [Abstract][Full Text] [Related]
36. Detection of Variants With Reduced Baloxavir Marboxil and Oseltamivir Susceptibility in Children With Influenza A During the 2019-2020 Influenza Season. Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Fujisaki S; Hashimoto K; Hosoya M J Infect Dis; 2021 Nov; 224(10):1735-1741. PubMed ID: 33837427 [TBL] [Abstract][Full Text] [Related]
37. Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil. Hashimoto T; Baba K; Inoue K; Okane M; Hata S; Shishido T; Naito A; Wildum S; Omoto S Influenza Other Respir Viruses; 2021 May; 15(3):389-395. PubMed ID: 33099886 [TBL] [Abstract][Full Text] [Related]
38. In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses. Kuroda T; Fukao K; Yoshida S; Oka R; Baba K; Ando Y; Taniguchi K; Noshi T; Shishido T Viruses; 2023 May; 15(5):. PubMed ID: 37243240 [TBL] [Abstract][Full Text] [Related]
39. Baloxavir Treatment Delays Influenza B Virus Transmission in Ferrets and Results in Limited Generation of Drug-Resistant Variants. Pascua PNQ; Jones JC; Marathe BM; Seiler P; Caufield WV; Freeman BB; Webby RJ; Govorkova EA Antimicrob Agents Chemother; 2021 Oct; 65(11):e0113721. PubMed ID: 34424039 [TBL] [Abstract][Full Text] [Related]
40. Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition. Jones JC; Pascua PNQ; Harrington WN; Webby RJ; Govorkova EA J Antimicrob Chemother; 2021 Mar; 76(4):957-960. PubMed ID: 33351916 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]